Arena Pharmaceuticals is a biotechnology business based in the US. Arena Pharmaceuticals shares (ARNA) are listed on the NASDAQ and all prices are listed in US Dollars. Arena Pharmaceuticals employs 448 staff and has a trailing 12-month revenue of around $54,000.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $99.99 |
|---|---|
| 52-week range | $0.00 - $0.00 |
| 50-day moving average | $93.49 |
| 200-day moving average | $70.91 |
| Wall St. target price | $97.86 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-10.14 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $99.99 from 2022-03-14
| 1 week (2024-07-16) | N/A |
|---|---|
| 1 month (2024-06-23) | N/A |
| 3 months (2024-04-23) | N/A |
| 6 months (2024-01-23) | N/A |
| 1 year (2023-07-23) | N/A |
|---|---|
| 2 years (2022-07-23) | N/A |
| 3 years (2021-07-27) | 63.06% |
| 5 years (2019-07-26) | 58.64% |
Valuing Arena Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Arena Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Arena Pharmaceuticals's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.46. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Arena Pharmaceuticals's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Arena Pharmaceuticals's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $549.8 million.
The EBITDA is a measure of a Arena Pharmaceuticals's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $54,000 |
|---|---|
| Gross profit TTM | $-419,455,000 |
| Return on assets TTM | -34.53% |
| Return on equity TTM | -70.3% |
| Profit margin | 0% |
| Book value | $10.94 |
| Market Capitalization | $6.2 billion |
TTM: trailing 12 months
We're not expecting Arena Pharmaceuticals to pay a dividend over the next 12 months.
Arena Pharmaceuticals's shares were split on a 1:10 basis on 18 June 2017. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Arena Pharmaceuticals shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Arena Pharmaceuticals shares which in turn could have impacted Arena Pharmaceuticals's share price.
Over the last 12 months, Arena Pharmaceuticals's shares have ranged in value from as little as $0 up to $0. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Arena Pharmaceuticals's is 0.5487. This would suggest that Arena Pharmaceuticals's shares are less volatile than average (for this exchange).
Arena Pharmaceuticals, Inc. , a biopharmaceutical company, focuses on providing novel medicines with pharmacology and pharmacokinetics to patients worldwide. The company's investigational clinical programs include Etrasimod (APD334) that is in Phase III clinical trial for ulcerative colitis, Phase IIb/III clinical trial for Crohn's disease, Phase II clinical trial for alopecia areata, Phase III clinical trial for atopic dermatitis, and Phase IIb clinical trial for eosinophilic esophagitis; Olorinab (APD371), which is in Phase IIb clinical trial for the treatment of abdominal pain associated with irritable bowel syndrome; APD418 that is in Phase II clinical trial for acute heart failure; and Temanogrel for coronary microvascular obstruction that is in Phase II clinical trial. It also develops ralinepag (APD811), which is in Phase III clinical trial for pulmonary arterial hypertension. The company has collaboration agreements with United Therapeutics Corporation; Everest Medicines Limited; Eisai Co. , Ltd. and Eisai Inc.
Trade commission-free stocks and ETFs with Opto, and stay ahead by spotting emerging trends through thematic investing.
Check out our picks of the best paper trading platforms to practice trading and investing with fake money.
Spot Ethereum ETFs might soon be approved. Here’s how to invest if and when they become available to trade.
Check out our picks for the brokers with the best cash sweep rates on uninvested cash.
These are the best day trading platforms, according to Finder’s comprehensive analysis.
Explore the best bonuses for opening a new brokerage account.
We’ve rounded up stats on some of the most popular semiconductor stocks, along with information on how they compare and how to invest.
Check out our picks of the best brokerage accounts for beginners, micro-investing, crypto trading and more.
What you need to know about investing in the leading indicator for the overall US stock market.
Check out our 7 ideas for how to invest $10K to maximize your money.